Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Breast Cancer

Presenters

Nuria Chic

Citation

Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239

Authors

N. Chic1, T. Pascual1, F. Brasó-Maristany2, P. Villagrasa Gonzalez3, L. Pare Brunet3, F. Schettini4, B. Conte5, B. Adamo6, M. Vidal6, M. Muñoz6, O. Martínez6, B. Gonzalez-Farre7, J. Cortés8, A. Llombart-Cussac9, V. Rodrik-Outmezguine10, M.A. Izquierdo Delso11, R. Schiff12, C..K. Osborne13, M. Rimawi13, A. Prat14

Author affiliations

  • 1 Translational Genomics And Targeted Therapeutics In Solid Tumors, Institut d'Investigaciones Biomèdiques August Pi i Sunyer, 08036 - Barcelona/ES
  • 2 Oncology, Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 - Barcelona/ES
  • 3 Scientific, SOLTI, 08007 - Barcelona/ES
  • 4 Oncology, Azienda Universitaria Ospedaliera Federico II, 80131 - Napoli/IT
  • 5 Medical Oncology  , Ospedale Policlinico San Martino, University of Genova, 16132 - Genova/IT
  • 6 Medical Oncology, Hospital Clinic, 08036 - Barcelona/ES
  • 7 Pathology Department, Hospital Clinic, 08036 - Barcelona/ES
  • 8 Oncology Department, IOB Institute of Oncology, Quironsalud Group, Madrid & Barcelona & Vall d´Hebron Intitute of Oncology (VHIO), Barcelona, 28034 - Madrid/ES
  • 9 Medical Oncology, Hospital Universitario Arnau de Vilanova, 46015 - Valencia/ES
  • 10 Oncology Precision Medicine, Novartis Pharmaceuticals Corporation, 07936-1080 - East Hanover/US
  • 11 Clinical Development & Analytics, Novartis Pharma AG, 4057 - Basel/CH
  • 12 Molecular And Cellular Biology, Baylor College of Medicine, 77030 - Houston/US
  • 13 Medical Oncology, Baylor College of Medicine, 77030 - Houston/US
  • 14 Medical Oncology  , Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4377

Background

The ALTERNATIVE trial randomized 355 patients (pts) with HER2+/HR+ metastatic BC to receive as 1st-line therapy lapatinib (L) + trastuzumab (T) + aromatase inhibitors (AI) or T + AI or L + AI. The neoadjuvant PAMELA trial tested a chemo-free regimen of L + T on HER2+ pts, combined with letrozole or tamoxifen in HR+ tumors. We explored the hypothesis that gene expression may help predicting benefit from anti-HER2 therapy in combination with ET.

Methods

The expression of 55 BC-related genes was evaluated from FFPE tumors using the nCounter. The PAM50 subtype distribution and the association of the expression of each gene (continuous variable) with progression-free survival (PFS) was evaluated using univariate Cox-models. Median PFS was calculated using the Kaplan-Meier method. Clinical benefit (CB) was defined as complete or partial response or stable disease at 6 months. The Cutoff Finder tool was used to find an optimal gene expression cut-off with CB as the endpoint. Logistic regression was used to evaluate the association of gene expression with pathologic complete resonse (pCR) and CB.

Results

In ALTERNATIVE, 60 tumors (16.9%) were analyzed: 57% HER2-enriched, 20% Luminal B, 12% Luminal A, 8% Normal-like and 3% Basal-like. Median PFS in ERBB2-high group (above the median) was higher compared to ERBB2-low group (11.0 vs 5.6 months; Hazard Ratio [HazR]=0.49; p = 0.006). ERBB2 was found more expressed in pts with CB. CB rate was higher in the ERBB2-high group compared to ERBB2-low group (54% vs 22%; p = 0.013). An optimal ERBB2 mRNA cutoff (2.923) for predicting CB (AUC=0.68; odds ratio [OR]=1.49, p = 0.014; PFS HazR=0.46, p = 0.022) was then identified. The same ERBB2 cutoff in PAMELA baseline tumor samples (n = 77) was found significantly associated with pCR (43.8% in ERBB2-high vs. 11.5% in ERBB2-low; adjusted OR = 4.45; p = 0.041).

Conclusions

ERBB2 mRNA expression is a robust predictor of response and survival outcome in HER2+/HR+ BC following HER2-blockade and ET. Our study identifies a common biomarker between pCR improvement (OR ∼4.5) in early disease and CB in the advanced setting (PFS HazR of ∼0.50).

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Institut d’investigacions Biomèdiques August Pi i Sunyer (IDIBAPS).

Funding

Has not received any funding.

Disclosure

N. Chic: Travel / Accommodation / Expenses: Eisai. F. Schettini: Travel / Accommodation / Expenses: Celgene; Travel / Accommodation / Expenses: Pfizer. M. Vidal: Speaker Bureau / Expert testimony: Novartis; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Eisai; Speaker Bureau / Expert testimony: Daiichi Sankyo. M. Muñoz: Travel / Accommodation / Expenses: Roche. J. Cortés: Honoraria (self): Novartis; Honoraria (self): Eisai; Honoraria (self): Roche; Advisory / Consultancy: Roche/Genentech; Advisory / Consultancy: Celgene; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Biothera Pharmaceutical; Advisory / Consultancy: Merus; Advisory / Consultancy: Seattle Genetics. A. Llombart-Cussac: Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche/Genentech. M. Rimawi: Advisory / Consultancy: GlaxoSmithKline; Advisory / Consultancy: Roche/Genentech; Advisory / Consultancy: MacroGenics; Advisory / Consultancy: Novartis; Advisory / Consultancy: Daiichi Sankyo. A. Prat: Advisory / Consultancy: Nanostring Techonologies. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.